Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/6/2024 | $10.00 | Buy | ROTH MKM |
| 1/5/2022 | $20.00 | Buy | EF Hutton |
8-K - Longeveron Inc. (0001721484) (Filer)
8-K - Longeveron Inc. (0001721484) (Filer)
8-K - Longeveron Inc. (0001721484) (Filer)
MIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the 4th Annual ROTH Healthcare Opportunities Conference. Longeveron management will host one-on-one meetings with investors at the conference to be held October 9, 2025 in New York. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (M
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a developer of ambulatory surgical centers (ASCs), and has participated in the selling of two ASCs with deal values totaling almost $1 billion. "I am delighted to welcome George, and his tremendous experience as a physician, inv
Exploring potential partnerships and strategic opportunities for the Company's stem cell therapy program in Alzheimer's diseaseAlzheimer's disease development program with positive data in successful Phase 1 and Phase 2a clinical trialsClear regulatory pathway following positive Type B meeting with U.S. FDAFDA has granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer's disease MIAMI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today
ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00
EF Hutton initiated coverage of Longeveron with a rating of Buy and set a new price target of $20.00
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a developer of ambulatory surgical centers (ASCs), and has participated in the selling of two ASCs with deal values totaling almost $1 billion. "I am delighted to welcome George, and his tremendous experience as a physician, inv
Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program. "We are delighted to have Than join Longeveron at this transformational time in the Company's
MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies. "We are delighted to have Devin join Longeveron at this transformational time in the Company's evolution," said Wa'el Hashad, Chief Executive Officer at Longeveron. "This appointment reinforces Longevero
MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13754295 Call meTM Feature:Click HereWebcast:Click Here An archived replay of the webcast will be available on t
Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in Nature MedicinePositive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer's disease; single, pivotal Phase 2/3 adaptive design clinica
MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number: 1.877.407.0789 Conference ID: 13752361 Call meTM Feature: Click HereWebcast: Click Here An archived replay of the webcast will be available o
SC 13G/A - Longeveron Inc. (0001721484) (Subject)
SC 13G - Longeveron Inc. (0001721484) (Subject)
SC 13G - Longeveron Inc. (0001721484) (Subject)